Stage Set For Next Checkpoint Inhibitor Battle within Bladder Cancer - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cancer Drug News Issue 669" report to their offering.

The predicted view that bladder cancer would represent the next battleground for checkpoint inhibition is playing out. Current leaders will maintain market position mid-term by leveraging first-to-market advantages and line extensions. Combination approaches represent considerable opportunity for shifting market dynamics and AstraZeneca's pipeline is highly populated by these programmes.

Key Topics Covered:

1 Stage Set For Next Checkpoint Inhibitor Battle

2. Breast Cancer

  • Ibrance Earnings Potential Unlocked Further
  • OBI-822/821 Phase II/III Trial Fails To Meet Primary Endpoint In MBC

3. Haematological Cancer

  • Novartis' PKC412 Granted FDA Breakthrough Therapy Status For AML Subtype
  • CAR-T Validation Increasing Confidence
  • Aranesp Phase III Study Meets Primary Endpoint In MDS Patients

4. Brain Cancer

  • Apogenix Secures Funding To Develop APG101 For Glioblastoma

5. General Developments

  • eFFECTOR Increases Funds To Advance Anti-Cancer Candidate
  • National Cancer Moonshot Mirrors Current Oncology Trends
  • BMS/Dana-Farber Cancer Institute Collaborate On I-O RPM Programme
  • Myriad Collaborates With Tesaro/Merck On Companion Diagnostic Research

6. Supportive Therapies

  • Helsinn/Mundipharma Enter Deal For Anamorelin In Northern Europe

7. Conference Listings

For more information visit http://www.researchandmarkets.com/research/2532xh/cancer_drug_news

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs